Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Treatment of children and adolescents with alveolar rhabdomyosarcoma (ARMS) and regional nodal involvement (N1) have been approached differently by North American and European cooperative groups. In order to define a better therapeutic strategy, we analyzed two studies conducted between 2005 and 2016 by the European paediatric Soft tissue sarcoma Study Group (EpSSG) and Children's Oncology Group (COG).
Methods: We retrospectively identified patients with ARMS N1 enrolled in either EpSSG RMS2005 or in COG ARST0531. Chemotherapy in RMS2005 comprised ifosfamide + vincristine + dactinomycin + doxorubicin (IVADo), IVA and maintenance (vinorelbine, cyclophosphamide); in ARST0531, it consisted of either vincristine + dactinomycin + cyclophosphamide (VAC) or VAC alternating with vincristine + irinotecan (VI). Local treatment was similar in both protocols.
Results: The analysis of the clinical characteristics of 239 patients showed some differences between study groups: in RMS2005, advanced Intergroup Rhabdomyosarcoma Study Group (IRS) and large tumors predominated. There were no differences in outcomes between the two groups: 5-year event-free survival (EFS), 49% (95% confidence interval [CI]: 39-59) and 44% (95% CI: 30-58), and overall survival (OS), 51% (95% CI: 41-61) and 53.6% (95% CI: 40-68) in RMS2005 and ARST0531, respectively. In RMS2005, EFS of patients with FOXO1-positive tumors was significantly inferior to those with FOXO1-negative (49.3% vs 73%, P = .034). In contrast, in ARST0531, EFS of patients with FOXO1-positive tumors was 45% compared with 43.8% for those with FOXO1-negative.
Conclusions: The outcome of patients with ARMS N1 was similar in both protocols. However, patients with FOXO1 fusion-negative tumors enrolled in RMS2005 showed a significantly better outcome, suggesting that different strategies of chemotherapy may have an impact in the outcome of this subgroup of patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414760 | PMC |
| http://dx.doi.org/10.1002/pbc.28832 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alveolar Rhabdomyosarcoma With Bone Marrow Metastases and Disseminated Intravascular Coagulation Mimicking Acute Lymphoblastic Leukemia: A Case Report.
Cureus
July 2025
Department of Hematology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, CHN.
Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children and adolescents, with some patients exhibiting bone marrow involvement. Leukemic presentations of RMS have been documented in the literature. However, distinguishing RMS with bone marrow metastasis from acute leukemia can be challenging due to their overlapping morphological features, particularly in the absence of a characteristic primary mass.
View Article and Find Full Text PDFPrevalence of locoregional and distant lymph node metastases in children and adolescents/young adults with soft tissue sarcomas: a Bayesian meta-analysis of proportions.
EClinicalMedicine
September 2025
Department of Pediatric Surgery and Urology, Centre for Pediatric Surgery, Philipps-University, University Hospital Giessen-Marburg, Baldingerstraße, Marburg 35043, Germany.
Background: The presence of both regional and distant lymph node metastases (LNM) in paediatric and adolescent/young adult (AYA) patients with soft tissue sarcomas (STS) significantly impacts clinical outcomes. However, reported rates of LNM vary widely across the literature and are often accompanied by substantial uncertainty. We aimed to quantitatively synthesise global proportions of LNM across different histological subtypes and tumour sites in this population.
View Article and Find Full Text PDFCDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma.
bioRxiv
July 2025
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
Alveolar rhabdomyosarcoma (aRMS) is a fusion-driven pediatric cancer with poor survival and limited therapeutic options. To uncover novel vulnerabilities, we employed complex-based analysis of the DepMap functional genomic data, identifying CDK8 as a dependency in aRMS. Both knockout and pharmacologic inhibition impaired tumor cell growth and induced myogenic differentiation and .
View Article and Find Full Text PDFPredictors of survival among children and adolescents with rhabdomyosarcoma treated in a single resource-limited centre -Uganda.
BMC Cancer
August 2025
Division of Paediatric Oncology, Uganda Cancer Institute, P.O. Box 3935, Kampala, Uganda.
Background: The treatment outcomes for children and adolescents with rhabdomyosarcoma (RMS) in low-income countries are poor. However, there is a paucity of literature on RMS and its management outcomes in low-resource settings. We evaluated the treatment of RMS with the aim of identifying prognostic factors during management to improve outcomes.
View Article and Find Full Text PDFCase Report of Maxillary Alveolar Rhabdomyosarcoma Misdiagnosed as Periapical Lesion: Clinicopathological Alerts and Life-Saving Lessons for Dentists.
Aust Endod J
August 2025
Department of Pathology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey.
This report describes a rare case of alveolar rhabdomyosarcoma initially presenting with clinical features resembling an endodontic lesion. A 15-year-old male presented with progressive right maxillary swelling initially treated as a dental abscess. Radiographic examination revealed a poorly defined destructive lesion associated with the apices of teeth #14-18, exhibiting expansion and destruction of the maxillary sinus walls.
View Article and Find Full Text PDF